Biomimetic cellular vectors for enhancing drug delivery to the lungs

  • Evangelopoulos M.
  • Yazdi I.
  • Acciardo S.
  • Palomba R.
  • Giordano F.
  • Pasto A.
  • Sushnitha M.
  • Martinez J.
  • Basu N.
  • Torres A.
  • Hmaidan S.
  • Parodi A.
  • Tasciotti E.
Дата публикации:01.12.2020
Журнал: Scientific Reports
БД: Scopus
Ссылка: Scopus


© 2020, The Author(s). Despite recent advances in drug delivery, the targeted treatment of unhealthy cells or tissues continues to remain a priority. In cancer (much like other pathologies), delivery vectors are designed to exploit physical and biological features of unhealthy tissues that are not always homogenous across the disease. In some cases, shifting the target from unhealthy tissues to the whole organ can represent an advantage. Specifically, the natural organ-specific retention of nanotherapeutics following intravenous administration as seen in the lung, liver, and spleen can be strategically exploited to enhance drug delivery. Herein, we outline the development of a cell-based delivery system using macrophages as a delivery vehicle. When loaded with a chemotherapeutic payload (i.e., doxorubicin), these cellular vectors (CELVEC) were shown to provide continued release within the lung. This study provides proof-of-concept evidence of an alternative class of biomimetic delivery vectors that capitalize on cell size to provide therapeutic advantages for pulmonary treatments.

Вернуться назад
про COVID-19